ARTICLE | Product Development
Growing IL-18 field looks to enhance cell therapies via decoy evasion
As more companies bring IL-18 into their cancer pipelines, they also bring new modalities and approaches to the cytokine’s inhibitory decoy receptor
January 26, 2024 1:26 AM UTC
Deals between major cancer cell therapy players and biotechs with strategies to promote IL-18 signaling unhampered by decoy receptors indicate the cytokine’s next wave of innovation will combine the two approaches.
Interest in IL-18’s capacity to boost tumor killing by immune cells has risen over the last five years through the convergence of multiple findings, including biomarker support for the cytokine’s role...